Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of Ginkgo biloba, a plant-derived dietary supplement with vasoregulatory and antioxidant properties, and methylprednisolone, a synthetic glucocorticoid corticosteroid used for its potent anti-inflammatory and immunosuppressive effects. Ginkgo biloba is thought to improve blood flow, reduce oxidative stress, and modulate platelet-activating factor. Methylprednisolone acts by binding to the glucocorticoid receptor to suppress inflammation and immune responses. The combination has been studied in clinical settings (primarily with other corticosteroids such as prednisone) for conditions like sudden sensorineural hearing loss, where it may improve hemorheological parameters (blood viscosity), immune cell profiles (T cell subsets), and overall symptom improvement compared to steroid monotherapy[2][5][9]. There are known pharmacodynamic interactions between these agents; co-administration may increase the risk or severity of adverse effects[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgo biloba + methylprednisolone.